Sarah Cannon Research Institute (SCRI) has named Anthony A. Meluch, M.D. as a primary investigator.
NASHVILLE, Tenn., May 11, 2005 -- Sarah Cannon Research Institute (SCRI) has named Anthony A. Meluch, M.D. as a primary investigator. A clinical researcher with The Sarah Cannon Cancer Center since 1993, Meluch is also a member of Tennessee Oncology, P.L.L.C.
Dr. Meluch joins SCRI's primary investigator team, directed by F. Anthony Greco, M.D., which also includes John D. Hainsworth, M.D., Howard A. Burris III, M.D., Denise A. Yardley, M.D., David Spigel, M.D. and Suzanne F. Jones, PharmD.
"Dr. Meluch is a thought leader who brings excellent qualifications and experience to our team," said Dr. Greco. "His research interests and passion for advancing patient care will enable us to expand our menu of clinical trials."
Meluch received his undergraduate training at St. Louis University in Missouri, and his medical doctorate from The Ohio State University College of Medicine. He completed an internal medicine residency program and then a fellowship in both hematology and oncology at the University of Alabama in Birmingham; he is board certified in all three subspecialties. His research interests and publications are in malignancies of the upper aerodigestive system, esophagus, head, neck and genitourinary tract.
"Dr. Meluch's vast knowledge and experience as a practicing physician and researcher made him the perfect candidate for this role," said Mark Cianciolo, CEO of Sarah Cannon Research Institute. "His appointment is in line with our goals to expand our team of physician researchers to enhance our ability to develop more clinical trials for more patients."
"I am honored and excited by the opportunity to further my research interests and expand the scope of SCRI's investigations to improve outcomes for people fighting cancer," said Dr. Meluch.
Sarah Cannon Research Institute, a new company created by HCA's MidAmerica Division and Tennessee Oncology, is dedicated to creating and advancing solutions for a healthier tomorrow through clinical research. The institute is the largest community-based research program in the United States, currently conducting clinical trials through a network of more than 600 oncologists in 25 states.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.